Overview

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

Status:
Recruiting
Trial end date:
2026-01-02
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.